| ADR Ontology |
| ADR Term |
Multiple sclerosis |
| ADR ID |
BADD_A02874 |
| ADR Hierarchy |
|
| Description |
An autoimmune disorder mainly affecting young adults and characterized by destruction of myelin in the central nervous system. Pathologic findings include multiple sharply demarcated areas of demyelination throughout the white matter of the central nervous system. Clinical manifestations include visual loss, extra-ocular movement disorders, paresthesias, loss of sensation, weakness, dysarthria, spasticity, ataxia, and bladder dysfunction. The usual pattern is one of recurrent attacks followed by partial recovery (see MULTIPLE SCLEROSIS, RELAPSING-REMITTING), but acute fulminating and chronic progressive forms (see MULTIPLE SCLEROSIS, CHRONIC PROGRESSIVE) also occur. (Adams et al., Principles of Neurology, 6th ed, p903) [MeSH] |
| MedDRA Code |
10028245 |
| MeSH ID |
D009103; D009103; D009103
|
|
ADR Severity Grade (FAERS)
|
|
|
ADR Severity Grade (CTCAE)
|
Not Available
|
| Synonym |
| Disseminated sclerosis | MS | MS aggravated | MS-like syndrome | Multiple sclerosis | Multiple sclerosis aggravated | Multiple sclerosis like syndrome | Multiple sclerosis-like syndrome | Sclerosis multiple | Syndrome MS-like | Progression of multiple sclerosis | Multiple Sclerosis | Sclerosis, Multiple | Sclerosis, Disseminated | Disseminated Sclerosis | MS (Multiple Sclerosis) | Multiple Sclerosis, Acute Fulminating |
|
|
| ADR Related Proteins |
| Protein Name |
UniProt AC |
TTD Target ID |
| Not Available | Not Available | Not Available |
|
| Drugs Leading to the ADR |
|
|
